AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UBS Group AG Director's Dealing 2024

Aug 29, 2024

998_dirs_2024-08-29_933f1ee5-7404-488d-ba04-5f4dde4163cd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2024-08-27

Reporting Person: UBS Group AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-27	Common Stock	P	3715	$0.5523	Acquired	146012	Indirect

Footnotes

F1: This Statement is filed jointly by UBS Group AG for the benefit and
on behalf of UBS Securities LLC
and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group